Selected article for: "clinical study and cohort study"
Author: Joo, Eun-Jeong; Ko, Jae-Hoon; Kim, Seong Eun; Kang, Seung-Ji; Baek, Ji Hyeon; Heo, Eun Young; Shi, Hye Jin; Eom, Joong Sik; Choe, Pyoeng Gyun; Bae, Seongman; Ra, Sang Hyun; Kim, Da Young; Kim, Baek-Nam; Kang, Yu Min; Kim, Ji Yeon; Chung, Jin-Won; Chang, Hyun-Ha; Bae, Sohyun; Cheon, Shinhyea; Park, Yoonseon; Choi, Heun; Lee, Eunjung; Lee, Bo young; Park, Jung Wan; Sohn, Yujin; Heo, Jung Yeon; Kim, Sung-Han; Peck, Kyong Ran
Title: Clinical and Virologic Effectiveness of Remdesivir Treatment for Severe Coronavirus Disease 2019 (COVID-19) in Korea: a Nationwide Multicenter Retrospective Cohort Study
  • Cord-id: bxcpkxn5
  • Document date: 2021_3_12
    • ID: bxcpkxn5
    Snippet: BACKGROUND: Remdesivir is widely used for the treatment of coronavirus disease 2019 (COVID-19), but controversies regarding its efficacy still remain. METHODS: A retrospective cohort study was conducted to evaluate the effect of remdesivir on clinical and virologic outcomes of severe COVID-19 patients from June to July 2020. Primary clinical endpoints included clinical recovery, additional mechanical ventilator (MV) support, and duration of oxygen or MV support. Viral load reduction by hospital
    Document: BACKGROUND: Remdesivir is widely used for the treatment of coronavirus disease 2019 (COVID-19), but controversies regarding its efficacy still remain. METHODS: A retrospective cohort study was conducted to evaluate the effect of remdesivir on clinical and virologic outcomes of severe COVID-19 patients from June to July 2020. Primary clinical endpoints included clinical recovery, additional mechanical ventilator (MV) support, and duration of oxygen or MV support. Viral load reduction by hospital day (HD) 15 was evaluated by calculating changes in cycle threshold (Ct) values. RESULTS: A total of 86 severe COVID-19 patients were evaluated including 48 remdesivir-treated patients. Baseline characteristics were not significantly different between the two groups. Remdesivir was administered an average of 7.42 days from symptom onset. The proportions of clinical recovery of the remdesivir and supportive care group at HD 14 (56.3% and 39.5%) and HD 28 (87.5% and 78.9%) were not statistically different. The proportion of patients requiring MV support by HD 28 was significantly lower in the remdesivir group than in the supportive care group (22.9% vs. 44.7%, P = 0.032), and MV duration was significantly shorter in the remdesivir group (average, 1.97 vs. 5.37 days; P = 0.017). Analysis of upper respiratory tract specimens demonstrated that increases of Ct value from HD 1–5 to 11–15 were significantly greater in the remdesivir group than the supportive care group (average, 10.19 vs. 5.36; P = 0.007), and the slope of the Ct value increase was also significantly steeper in the remdesivir group (average, 5.10 vs. 2.68; P = 0.007). CONCLUSION: The remdesivir group showed clinical and virologic benefit in terms of MV requirement and viral load reduction, supporting remdesivir treatment for severe COVID-19.

    Search related documents:
    Co phrase search for related documents
    • activity limit and lung disease: 1
    • acute sars cov respiratory syndrome coronavirus and administration timing: 1, 2, 3, 4, 5, 6, 7, 8
    • acute sars cov respiratory syndrome coronavirus and admission day: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and admission symptom onset: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute sars cov respiratory syndrome coronavirus and admission time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and live discharge: 1
    • acute sars cov respiratory syndrome coronavirus and liver function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and liver function test: 1, 2, 3, 4, 5, 6
    • acute sars cov respiratory syndrome coronavirus and load reduction: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and low respiratory tract: 1, 2, 3, 4, 5
    • acute sars cov respiratory syndrome coronavirus and lrt specimen: 1, 2
    • acute sars cov respiratory syndrome coronavirus and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • administration timing and load reduction: 1
    • administration timing and lopinavir ritonavir: 1, 2, 3
    • administration timing and lung disease: 1, 2, 3
    • admission day and liver function test: 1, 2
    • admission day and lrt specimen: 1
    • admission day and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12